Have you or your loved ones been diagnosed with advanced solid tumors?

You may be eligible to participate in a advanced solid tumors clinical trial.

Have you or your loved ones been diagnosed with advanced solid tumors? You may be eligible to participate in a advanced solid tumors clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Advanced Solid Tumors Clinical Trial
NCT03000257 | Phase 1 | Interventional
AbbVie
Sponsored by
AbbVie

Have you or your loved ones been diagnosed with advanced solid tumors?

You may be eligible to participate in a advanced solid tumors clinical trial.

Have you or your loved ones been diagnosed with advanced solid tumors? You may be eligible to participate in a advanced solid tumors clinical trial.

Active not recruiting

Male & Female

18 Years +

This study has recruited 182 Participants

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab. This study will also evaluate the safety and tolerability of budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax. The study will consist of 3 parts: budigalimab monotherapy dose escalation and expansion, budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax.